-
公开(公告)号：US09994581B2
公开(公告)日：2018-06-12
申请号：US15103215
申请日：2014-12-10
Applicant: AbbVie Inc.
Inventor： Le Wang , Robin R. Frey , Todd M. Hansen , Dachun Liu , William J. McClellan , Keith F. McDaniel , John K. Pratt , Carol K. Wada
IPC: C07D491/22 , C07D491/056 , A61K45/06 , A61K31/4353 , C07D491/153
CPC classification number: C07D491/056 , A61K31/4353 , A61K45/06 , C07D491/153 , C07D491/22
Abstract: The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
公开(公告)号：US20170015673A1
公开(公告)日：2017-01-19
申请号：US15103215
申请日：2014-12-10
Applicant: ABBVIE INC.
Inventor： Le Wang , Robin R. Frey , Todd M. Hansen , Dachun Liu , William J. McClellan , Keith F. McDaniel , John K. Pratt , Carol K. Wada
IPC: C07D491/056 , C07D491/153
CPC classification number: C07D491/056 , A61K31/4353 , A61K45/06 , C07D491/153 , C07D491/22
Abstract: The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中Rx，X，Y，Y1，L1，A1，A2，A3，A4，A5，A6，A7和A8具有说明书中定义的任何值， 其药学上可接受的盐，其可用作治疗疾病和病症（包括炎性疾病，癌症和AIDS）的药剂。 还提供了由一种或多种式（I）化合物组成的药物组合物。
-
公开(公告)号：US20160235716A1
公开(公告)日：2016-08-18
申请号：US14857419
申请日：2015-09-17
Applicant: ABBVIE INC.
Inventor： Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC: A61K31/4184 , C07D403/06 , C07D405/06 , A61K31/423 , C07D401/06 , A61K31/4439 , C07D263/52 , C07D235/02 , C07D409/06
CPC classification number: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
Abstract translation: 具有式（IX）结构的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中R1，R2a，R2b，R3a，R3b，R4a，R4b，Q1- - -Q2，R6，R7，A，B ，W，x和y如本文所定义并提供。 还提供了包含这些化合物的药物组合物和通过施用这些化合物治疗各种HAT相关病症或疾病（包括癌症）的方法。
-
4.发明授权Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases 有权Bcl-2选择性细胞凋亡诱导剂用于治疗癌症和免疫疾病公开(公告)号：US09125913B2
公开(公告)日：2015-09-08
申请号：US14058159
申请日：2013-10-18
Applicant: AbbVie Inc.
Inventor： Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura A. Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
IPC: A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/14 , C07D309/14 , C07D401/12 , C07D405/12 , C07D405/14 , C07D417/12 , C07D471/04 , A61K31/407 , A61K45/06 , C07D241/04 , C07D401/06 , C07D403/06 , C07D405/06 , C07D413/06 , C07D487/04
CPC classification number: C07D401/12 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D209/32 , C07D211/58 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D241/04 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/04 , C07D309/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/06 , C07D417/12 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡Bcl-2或Bcl-xL蛋白的活性的化合物，含有该化合物的组合物和治疗疾病的方法，其中表达抗凋亡Bcl-2蛋白。
-
公开(公告)号：US20140187531A1
公开(公告)日：2014-07-03
申请号：US14195666
申请日：2014-03-03
Applicant: AbbVie Inc.
Inventor： Milan Bruncko , Hong Ding , Steven W. Elmore , Aaron R. Kunzer , Christopher L. Lynch , William J. McClellan , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Xilu Wang , Noah P. Tu , Michael D. Wendt , Alexander R. Shoemaker , Michael J. Mitten
IPC: C07D295/155 , C07D209/52 , C07D405/12 , C07D211/34 , C07D491/048 , C07D451/02 , C07D233/22 , C07D207/08 , C07D205/04
CPC classification number: C07D295/155 , C07C311/51 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/20 , C07D207/24 , C07D207/50 , C07D209/02 , C07D209/52 , C07D211/14 , C07D211/20 , C07D211/26 , C07D211/34 , C07D211/38 , C07D211/42 , C07D211/46 , C07D211/48 , C07D211/58 , C07D211/62 , C07D211/70 , C07D211/72 , C07D213/36 , C07D213/38 , C07D213/42 , C07D213/70 , C07D213/74 , C07D213/81 , C07D213/82 , C07D215/12 , C07D231/12 , C07D231/56 , C07D233/06 , C07D233/22 , C07D233/24 , C07D233/61 , C07D233/64 , C07D235/08 , C07D239/06 , C07D239/20 , C07D239/38 , C07D241/04 , C07D249/18 , C07D257/04 , C07D261/20 , C07D263/12 , C07D263/22 , C07D263/58 , C07D265/30 , C07D267/10 , C07D273/01 , C07D277/04 , C07D277/36 , C07D277/74 , C07D295/185 , C07D295/30 , C07D307/14 , C07D307/22 , C07D307/81 , C07D309/14 , C07D309/20 , C07D317/66 , C07D333/20 , C07D333/34 , C07D335/02 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/10 , C07D413/04 , C07D451/02 , C07D471/08 , C07D487/04 , C07D487/08 , C07D491/04 , C07D491/048 , C07D491/08 , C07D498/08
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.
Abstract translation: 公开了抑制抗凋亡蛋白家族成员的活性的化合物，含有化合物的组合物和该化合物用于制备用于治疗疾病的药物的用途，其中发生表达一种或多种抗凋亡蛋白家族成员。
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20140107119A1
公开(公告)日：2014-04-17
申请号：US14081940
申请日：2013-11-15
Applicant: AbbVie Inc.
Inventor： Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura A. Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt , Todd M. Hansen
IPC: A61K31/5377 , A61K31/496 , C07D295/155 , A61K45/06 , C07D215/14 , C07D405/12 , C07D209/20 , C07D309/32 , C07D231/56
CPC classification number: C07D215/14 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D209/20 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/13 , C07D295/14 , C07D295/155 , C07D309/08 , C07D309/14 , C07D309/32 , C07D401/12 , C07D405/12 , C07D417/12 , C07D487/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
-
7.发明申请BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES 审中-公开用于治疗癌症和免疫疾病的BCL-2-选择性病毒诱导剂公开(公告)号：US20140057889A1
公开(公告)日：2014-02-27
申请号：US14058159
申请日：2013-10-18
Applicant: AbbVie Inc.
Inventor： Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura A. Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
IPC: A61K31/5377 , A61K31/496 , C07D413/06 , C07D401/06 , A61K45/06 , A61K31/407 , C07D403/06 , A61K31/501 , C07D241/04 , A61K31/495 , C07D405/06 , C07D487/04
CPC classification number: C07D401/12 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D209/32 , C07D211/58 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D241/04 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/04 , C07D309/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/06 , C07D417/12 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡Bcl-2或Bcl-xL蛋白活性的化合物，含有化合物的组合物和治疗疾病的方法，其中表达有抗凋亡Bcl-2蛋白。
-
公开(公告)号：US20180296566A1
公开(公告)日：2018-10-18
申请号：US16012379
申请日：2018-06-19
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada
IPC: A61K31/541 , A61K45/06 , C07D487/04 , C07D471/04 , A61K31/5025 , A61K31/437 , A61K31/5377
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
公开(公告)号：US20180193315A1
公开(公告)日：2018-07-12
申请号：US15907597
申请日：2018-02-28
Applicant: AbbVie Inc.
Inventor： Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC: A61K31/4184 , C07D403/06 , C07D498/10 , A61K31/4439 , A61K31/423 , C07D405/06 , C07D409/06 , C07D403/12 , C07D413/14 , C07D235/02 , C07D401/12 , C07D407/12 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D263/52 , C07D491/107 , C07D493/10 , C07D495/10 , C07D401/06
CPC classification number: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
公开(公告)号：US20160237084A1
公开(公告)日：2016-08-18
申请号：US15137502
申请日：2016-04-25
Applicant: AbbVie Inc.
Inventor： Le Wang , John Pratt , Lisa A. Hasvold , Dachun Liu , Yujia Dai , Steven D. Fidanze , James H. Holms , Robert A. Mantei , Keith F. McDaniel , George S. Sheppard , William J. McClellan
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中R 1，R 2，R 3，R 4和R 5具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗疾病和病症的试剂 ，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.063 seconds)
